The growth hormone-releasing hexapeptide (GHRP-6) specifically stimulates growth hormonc (GH) secretion in several animal species and humans. The mechanism of action of GHRP-6 is largely unknown, although experimental evidence indicates that it may modulate growth hormone-releasing hormone (GHRH) and somatostatin actions at the pituitary or hypothalamic level. To gain more insight into the mechanism(s) of action of GHRP-6, we studied the infant rat, an animal model highly responsive to GH-releasing stimuli. In 14-d-old rats GHRP-6 (32-600 pgikg, LC.) induced a marked and dose-dependent rise in plasma GH concentrations, maximal stimulation occurring with the dose of 300 pgikg. Neither GHRH nor somatostatin antiserum prevented or modified the G H release elicited by GHRP-6. In pups passively immunized with GHRH antibodies, a 5-d treatment with GHRP-6 (80 pgikg, s.c., twice daily) completely counteracted the inhibitory effect of GHRH deprivation on G H mRNA expression. It1 GHRP-6 is a synthetic peptide that specifically stimulates growth hormone release in all species so far investigated (1-3). Although GHRP-6 has been shown to stimulate GH release irz virro from rat primary pituitary cell cultures (4, 5), it shows a far greater GH-releasing activity when administered in viva (6)(7)(8). These observations suggest that GHRP-6 stimulates GH secretion by acting Received December h, 1993 iitro GHRP-6 ( I W 7 and 10 " M) induced a small and transient stimulation of G H release from cultured pituitary cells. These results indicate the following: I) GHRP-6 is a potent stimulator of G H release in rat pups; 2) it stimulates G H gene expression in the GHRH-deprived pup; .?) during the neonatal period its action is not mediated by GHRH or somatostatin; and 4) its actions are not directed at the somatotrophs. (Pediatr Res 36: 169-174, 1994) Abbreviations GHRP-6, growth hormone-releasing hexapeptide GH, growth hormone GHRH, growth hormone-releasing hormonc GHRH-ab, antiserum against growth hormone-releasing hormone somatostatin-ab, antiserum against somatostatin NRS, normal rabbit serum on two sites, the pituitary and the hypothalamus. In keeping with these findings, receptor binding sites for GHRP-6 have been demonstrated in both tissues (9). Experimental evidence has indicated that GHRP-6 does not bind to the GHRH receptor (7) or activate adenylate cyclase (4). However, in vivo studies have shown that GHRP-6 potentiates the GH-releasing effect of GHRH when the peptides are coadministered into humans (8) or adult rats (lo), and passive immunization against GHRH attenuates the GH response to GHRP-6 (11). Overall, it appears that in vitro results imply independent mechanisms for GHRP-6 and GHRH at the level of the pituitary Supported by NIH Grants ROIDK3X324 and KO4DKOIX74.
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To gain more insight into the mechanism(s) underlying the GH-releasing activity of GHRP-6, we used the infant rat, an animal model well suited for evaluating GHreleasing stimuli (12-14). First, we evaluated the GHreleasing effect of increasing doses of GHRP-6 in vivo. We then tested the GH-releasing effect of GHRP-6 in vitro and compared it to that occurring after GHRH. We then studied the involvement of GHRH and somatostatin in the mechanism of action of GHRP-6 by the use of passive immunization with specific antisera against GHRH and somatostatin. Finally, we evaluated the capacity of GHRP-6 to affect pituitary GH gene expression in rats deprived since birth of endogenous GHRH.
METHODS

Animals
Male and female 10-and 14-d-old Sprague-Dawley rats (Charles River Breeding Laboratories, Calco, Italy) weighing approximately 25 and 35 g, respectively, were used. They were received on the day of birth and were housed under controlled conditions (22 2 2"C, 65% humidity and artificial light from 0600-2000 h). A standard dry diet and water were available ad libitum to the dams. One hour before the experiments, pups were separated from their respective dam and were randomly divided into groups of eight. All the experiments were performed in accordance with the Italian Guidelines for the Use of Animals in Medical Research.
Antiserum to GHRH and Somatostatin
The GHRH-ab, prepared and validated by one of us (W.B.W.), has been repeatedly found to inhibit normal GH secretion and slow growth (15-18). In a previous study (16) we evaluated the effect of GHRH-ab (50-200 pL/rat) injected into 10-d-old rats on GH secretion. On the basis of that study, a dose of 100 pL/rat was chosen because it maximally inhibited GH secretion. The somatostatin-ab was prepared by immunizing rabbits with synthetic somatostatin conjugated to BSA and glutaraldehyde. The antiserum is directed toward the middle part of somatostatin and does not cross-react with other hypothalamic, pituitary, and gastrointestinal peptide hormones. One hundred FL of the undiluted antiserum were able to neutralize approximately 600 ng of somatostatin, an amount that greatly exceeds that present in the 14-dold rat.
Experimental Procedure
In vivo experiments. In the first series of experiments pups received a single S.C. injection of different doses of GHRP-6 (Bachem, Bubendorf, Switzerland) (i.e. 0, 16, 32, 150, 300, and 600 &kg dissolved in physiologic saline). Animals were killed by decapitation 20 min later.
In the second experiment, pups received a S.C. injection of 100 p L of a GHRH-ab (15) or somatostatin-ab (13) or 100 p L of both antiserum (GHRH-ab + somatostatinab), or 100 p L NRS. One h later they received a S.C. injection of GHRP-6 (300 p.g/kg) and were killed by decapitation 20 min after GHRP-6 injection. Trunk blood was collected and immediately centrifuged. Serum samples were stored at -20°C until assayed for GH.
In the third experiment aimed at evaluating the ability of GHRP-6 to stimulate GH synthesis, pups were given GHRH-ab (100 pLlrat) on d 1, 2, 4, 6, 8, and 10 of age. Control-treated rats received an equal volume of NRS. Beginning on d 6 or 8 and up to d 10, pups were given GHRP-6 (80 pg/kg, s.c., twice daily) or physiologic saline. Twelve h after the last administration of GHRP-6, pups were killed, and the pituitary gland was quickly dissected and frozen on dry ice for the determination of GH gene expression.
In vitro experiments. Pups were killed by decapitation, and the pituitary glands were rapidly dissected. Pituitary tissue used for cell dissociation included both the anterior and posterior lobes. Briefly, pituitary glands were collected in sterile F-10 medium (Sigma Chemical Co., St. Louis, MO). Tissue was cut into small fragments and incubated twice for 15 min at 37°C in F-10 medium containing 6% FCS and collagenase (2.5 mg/mL) (Boehringer, Mannheim GmBH, Germany). Fragments were then washed in Dulbecco's PBS, Ca2+-and free medium (Sigma Chemical Co.), and mechanically dissociated. Single-cell suspensions were plated onto 24-well (2 x 10' cellslwell) culture plates. The cells were incubated in F-10 medium supplemented with 10% horse serum, 4% FCS, and gentamycin (25 kg/mL) in a humidified atmosphere of 5% CO, and 95% air at 3TC. After 3 d, the medium was removed, and the cells were washed twice with serum-free F-10. The cells were then incubated in 1 mL of F-10 containing 0.1% BSA with no G H secretagogue or GHRP-6 (lo-", lo-', lo-' M) or GHRH (human GHRH-44, lo-' M; Bachem, Philadelphia, PA) or GHRP-6 lo-' M plus GHRH lo-' M. Media collected at the end of 15-and 30-min incubations were immediately frozen and stored at -20°C until assayed for GH content.
Pituitary GH Gene Expression
Total RNA was isolated by a single-step, acid guanidium thiocyanate-phenol-chloroform extraction method (19) . Total RNA samples (20 pg/sample) were run on a 1.2% formaldehyde agarose gel and transferred to nylon membranes (Hybond N, Amersham, Little Chalfont, UK). The membranes were hybridized with a cDNA probe specific for rat GH (kindly provided by F. De Noto, University of California, San Francisco, CA). The cDNA probe was labeled by random primer (Megaprime, Amersham) with O~-" P C~C T P to a specific activity of 1 x 10' dpmlpg DNA. The nylon filters were rehybridized with a "~-" P~~c T P labeled rat glyceraldehyde 3-phosphate dehydrogenase (G3PDH) probe to control for homogeneity of RNA loading. Autoradiography was carried out at -70°C for 16-24 h with intensifying screens. Quan-GHRP-6 STIMULATION OF GH mRNA AND RELEASE tification of hybridization signal was performed on a scanning densitometer (LKB XL, Laser Densitometer, Uppsala, Sweden). Pituitary GH mRNA levels were expressed as percentage of control group values.
GH Assay
GH concentrations in serum and in the pituitary culture media were measured by RIA with materials kindly provided by the National Institute of Diabetes, Digestive and Kidney Diseases of the National Institutes of Health. Values are expressed in terms of National Institute of Diabetes and Digestive and Kidney Diseases-rat-GH-RP-2 standard (potency 2 IU/mg) as pg/L of plasma or medium. The minimum detectable value of rat GH was 1.0 p a ; intraassay variability was 6%. To avoid interassay variations, we assayed samples from each experiment within one RIA.
Statistical Analysis
Statistical differences were evaluated by the Dunnett's r test for multiple comparisons, preceded by analysis of variance. A p value less than 0.05 was considered significant.
RESULTS
Preliminary experiments had indicated that in rat pups serum GH levels peaked 20 min after the s.c. injection of GHRP-6 (data not shown). Therefore, blood samples from all subsequent studies were collected at that time. Administration of GHRP-6 elicited a marked ( p < 0.05) rise in plasma G H concentrations at doses of 32, 150,300, and 600 pg/kg (272, 327, 456, and 411% increase over saline-treated rats, respectively). The dose of 16 pgkg did not stimulate GH secretion and that of 300 pg/kg resulted in a maximal response (Fig. 1) .
GHRP-6 and M) stimulated GH release from primary pituitary cell cultures at 15 min (increase over basal levels, 47 and 37% for GHRP-6 10-"nd M, respectively, p < 0.05); however, such stimulation was not observed at 30 min of incubation. At both time intervals, GHRP-6 M) failed to stimulate GH release (Fig. 2) . GHRH (lo-' M) alone or in combination with GHRP-6 (lo-' M) was effective in stimulating GH release at 15 (increase over basal levels, 43 and 52% for GHRH alone and GHRH + GHRP-6, respectively) and 30 min (47 and 52% for GHRH and GHRH + GHRP-6, respectively) (Fig. 2) . The action of the two peptides was neither additive nor synergistic.
In vivo, 1 h after GHRH-ab administration, basal plasma GH levels were significantly reduced. No significant effect was evident on basal GH levels after treatment with somatostatin-ab or the combination of the two antisera. G H significantly increased in response to GHRP-6 (300 pgkg, s.c.), and this response was not altered by antiserum pretreatment (Fig. 3) .
GHRP-6 (pg/kg) (Fig. 4) . GHRP-6 replacement therapy from d 8-10 of age resulted in only a slight increase in GH gene expression (21% increase versus GHRH-ab + salinetreated pups), but replacement therapy from d 6-10 resulted in full restoration of the GH mRNA expression to control levels (74% increase over GHRH-ab + salinetreated rats; p < 0.05). GHRP-6 treatment did not stimulate GH mRNA expression in the NRS-treated rats.
DISCUSSION
GHRP-6 elicited a marked, dose-related rise in plasma GH in infant rats. Its effects were apparently independent of endogenous GHRH and somatostatin release. Indeed, under our experimental conditions, functional blockade of the hypothalamic control of GH secretion by passive immunization with specific antisera against GHRH and somatostatin failed to alter GHRP-6-induced GH secretion. In infant rats after short-term GHRH deprivation, the hexapeptide was an effective stimulator of GH gene expression. However, in pituitary cultures GHRP-6 poorly and transiently stimulated GH release. Thus, we conclude that in infant rats: 1) GHRP-6 is a potent stimulator of GH release; 2) its action occurs primarily at the hypothalamic level; 3) the mode of action of GHRP-6 is independent from the classic neuroendocrine control of the hypothalamus; and 4) GHRP-6 is a stimulator of GH gene expression in GHRH-deprived rats.
Our data in the infant rat contrast those obtained in adult rats. Clark et al. (11) and Bercu et al. (10) have shown that in the adult rat passive immunization against GHRH produced partial or nearly complete suppression of GHRP-6 activity, indicating that in the adult rat GHRH is a prerequisite for full expression of GHRP-6 activity. In this vein, it has been shown that systemic GHRP-6 administration activates subpopulations of GHRH neurons in the rat arcuate nucleus (20) . However, several reports have been presented suggesting that GHRP-6 and GHRH operate by distinct receptors (4, 6, 21, 22) .
Inhibition of endogenous somatostatin activity has also been proposed as a mechanism of GHRP-6 action in the adult rat (11) and in humans (23) . However, in our hands depletion of hypothalamic somatostatin stores by cysteamine (24) did not impair the GH-releasing effect of GHRP-6 in adult rats (25) . The reason for the discrepancies between these results and those of the present study may reside in the age of the animals studied. Infant rats, when compared with adult rats, are more sensitive to G H secretagogues (12, 13, 26-28) but less sensitive to the inhibitory control of somatostatin (29) .
Proper interpretation of GHRP-6 mechanism of action is further compounded by recent data on GHRP-6 stimulation of GH secretion in rats with surgical ablation of the hypothalamus (25, 30) and in hypophysectomized rats bearing ectopic pituitary grafts (30) . It is possible that GHRP-6 stimulates GH secretion in vivo through several pathways. For example, stimulation may involve some uncharacterized hypothalamic factor, some specific pituitary receptor, or some unknown peripheral factor. The relative weight of such mechanism(s) in mediating GHRP-6 action in infants rats may be different than in adult rats. It has been shown that stimuli that are inefreceptor, present in the adult pituitary (Y), is not expressed or is functionally immature.
In conclusion, the present study indicates that in infant rats: 1) GHRP-6 is a potent stimulator of GH release; 2) it stimulates GH gene expression in the GHRH-deprived pup; 3) its action is not mediated by GHRH or somatostatin; and 4) its site of action is not on the somatotrophs. fective on the adult rat pituitary, such as thyrotropinreleasing hormone, y-aminobutyric acid, and galanin are REFERENCES GHRP-6's ability to stimulate GH gene expression may 
